Oct. 13 (Thu.) ,2016 13:15-14:15

Annex Hall

Japanese Session


Japan from the Viewpoint of Global Pharmaceutical Companies
-Its Value and Future Opportunities as a Place for the Development of Regenerative Medicine-

EFPIA Japan represents 24 R&D-based pharmaceutical companies, and is the voice of the European innovative pharmaceutical industry in Japan. To achieve our mission, ‘contribute to the welfare of the Japanese population through the provision of innovative pharmaceuticals and vaccines without delay’, we engage in activities such as provision of global best practices and dialogue with decision makers within Japan.
In this seminar we will focus on ‘the development of regenerative medicine products in Japan’, gaining lots of attention from the world after the establishment and implementation of relevant legal systems corresponding to early practical action for use of regenerative medicine. Speakers from pharma will share with attendees the example of simultaneous development, gap and the insight on legal frame, and the expectations of the drug pricing system. Thus in panel session, we hope to discuss the future outlook of the biopharmaceutical market in Japan.


Shinichi Ejima

Senior Managing Director, Novo Nordisk Pharma / Committee Chair, EFPIA Japan Biologics Committee

Expectation to Bio Industry in Japan

Simon Collier

Director General, EFPIA Japan

Regenerative Medicine Development Strategy – Challenge to Global Simultaneous Development

Yasuko Terao

Director, Clinical sicence Division, R&D, Janssen Pharmaceutical

Key Findings around Denelopment of Regenerative Medicines – Gene Therapy and Cartagena Act

Satoru Hayata

Chair, Biological Products Sub-committee / Head of Rare Disease Medicine Development Center - Japan, GlaxoSmithKline

Biological Products: Price to Value

Kuniyuki Hara

Corporate Officer, Head of External Affairs, Sanofi

Close Window